FDA Contributes Funds To Industry Post-Stenting Antiplatelet Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
The 20,000-patient dual antiplatelet therapy trial announced in October and slated to start enrolling patients this fall, likely will cost upward of $100 million, with most of the funds coming from industry.